OncoSec Medical has started the Phase II KEYNOTE-890 clinical trial of Tavo for the treatment of late-stage triple negative breast cancer (TNBC).

Tavo (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electroporation) will be trialled in combination with Merck’s Keytruda (pembrolizumab).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multicentre, open-label trial is expected to enrol patients with histologically confirmed diagnosis of inoperable locally advanced or metastatic TNBC, and at least one prior line of approved systemic chemotherapy or immunotherapy.

It represents the second Phase II OncoSec trial involving a combination of Tavo and Keytruda.

OncoSec’s first Phase II trial of Tavo and Keytruda, PISCES/KEYNOTE-695, is a global and multicentre study that examined the drug combination for metastatic melanoma.

Currently, overall survival for metastatic TNBC is one to two years from diagnosis, with therapies resulting in short-lived responses and/or significant toxicity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We believe that Tavo, in combination with Keytruda, has the potential to be effective in treating this disease.”

OncoSec Medical president and CEO Daniel O’Connor said: “Our goal is to enrol this study as quickly as possible and provide preliminary topline data in 2019.

“New approaches are desperately needed, and based on prior and ongoing clinical research, we believe that Tavo in combination with Keytruda has the potential to be effective in treating this disease.

“Given the severe unmet medical need, it is possible that Tavo for the treatment of TNBC could be granted Fast Track designation, Breakthrough Therapy designation, and be a candidate for accelerated approval.”

TNBC is a poor-prognosis breast cancer subtype, with limited treatment options for the patients.

OncoSec has been developing Tavo as a potential treatment for a number of cancer indications, either as a monotherapy or in combination with checkpoint inhibitors such as Keytruda.

Recently revealed results from clinical studies of Tavo have shown the drug as a local immune response and, subsequently, a systemic effect as either a monotherapy or combination treatment.